Table 2.
Immune mediator | Mdn concentration in patients with pOT, n = 21 (IQR) (pg/ml) | Mdn concentration in patients with rOT, n = 30 (IQR) (pg/ml) | Mdn concentration in patients in the control group, n = 11 (IQR) (pg/ml) | pOT vs control p value | rOT vs control p value | pOT vs rOT p value |
---|---|---|---|---|---|---|
T cell development-promoting cytokine | ||||||
IL-2 | 183 (0, 315) | 123 (0, 233) | 0 (0, 0) | <0.001 | 0.003 | 0.324 |
Th1-cytokines | ||||||
IFN-γ | 760 (218, 2.93∗103) | 348 (62.7, 909) | 0 (0, 0) | <0.0001 | <0.001 | 0.129 |
TNF-α | 55.2 (15.6, 111.4) | 22.6 (4.53, 64.9) | 0 (0, 0) | <0.00001 | <0.001 | 0.104 |
Th1 cell development-promoting cytokines | ||||||
IL-12p70 | 233 (114, 423) | 132 (81.2, 289) | 192 (158, 384) | 0.761 | 0.205 | 0.241 |
IL-7 | 654 (464, 1.19∗103) | 450 (318, 937) | 772 (532, 851) | 0.916 | 0.097 | 0.028 |
IL-15 | 79.8 (39.9, 217) | 47.5 (12.5, 136.5) | 0 (0, 23.4) | <0.0001 | 0.004 | 0.084 |
Th2 cytokines | ||||||
IL-4 | 29.4 (4.48, 59.6) | 16.2 (0, 38.6) | 0 (0, 0) | <0.0001 | <0.001 | 0.183 |
IL-5 | 49.2 (22.8, 149) | 37.1 (15.5, 93.6) | 0 (0, 0) | <0.0001 | <0.001 | 0.380 |
IL-9 | 135 (58.7, 345) | 93.5 (14.9, 205) | 0 (0, 0.62) | <0.00001 | 0.001 | 0.054 |
IL-10 | 67.9 (2.43, 176) | 19.8 (0, 102) | 1.99 (1.59, 49.8) | 0.106 | 0.521 | 0.188 |
IL-13 | 345.4 (204, 1.05∗103) | 194 (77.9, 647) | 230 (103, 286) | 0.022 | 0.402 | 0.051 |
Th17 cytokines | ||||||
IL-17 | 79.9 (0, 371) | 0 (0, 234) | 0 (0, 0) | 0.001 | 0.014 | 0.237 |
IL-1Rα | 262 (53.5, 648) | 130 (0, 337) | 0 (0, 0) | <0.0001 | 0.002 | 0.207 |
Th17 cell development-promoting cytokines | ||||||
IL-6 | 2.74∗103 (738, 6.01∗103) | 1.06∗103 (173, 3.99∗103) | 150 (1.54, 409) | <0.0001 | 0.004 | 0.108 |
IL-1β | 3.96 (0.57, 8.11) | 1.38 (0, 5.36) | 0 (0, 1.49) | 0.003 | 0.032 | 0.220 |
pOT: primary OT; rOT: recurrent OT: Mdn: median; IQR: interquartile range; significant p values are shown in bold; italic values are below LLOQ as defined by the manufacturer.